retatrutide weight loss results clinical trials Results:Trial Data and FDA Status Drug retatrutide helps people lower

The hormone releases in natural pulsatile patterns rather than the flat, continuous levels produced by direct growth hormone injection

This is also why retatrutide is being studied for metabolic dysfunction-associated steatotic liver disease (MASLD), where reducing liver fat is a primary clinical goal

These molecules can trigger the release of two hormones linked to curbing hunger: GLP-1 and PYY (peptide YY)

Retatrutide skin sensitivity has also been observed with other GLP-1 type medications, suggesting it may be a class-wide effect rather than something unique to Retatrutide alone

Full safety data from all seven TRIUMPH trials will provide a more complete picture as results are published throughout 2026

The primary goal of treatment should extend beyond weight loss to encompass the preservation of lean mass, improvement in metabolic health, and long-term prevention of obesity-related complications [7]